Background & Aims

The prevalence of migraine is estimated at nearly 20% of the adult population, with a clear female predominance (sex ratio 0.33 M/F). Mostly expressive for 20-50 year olds. New knowledge in pathophysiology and biotherapy has changed the evolutionary profile of migraine headaches.
Mainly, our objective is to demonstrate the arguments of central sensitization as a means of neuromodulation of migraine pain, and secondarily to highlight the interest of biotherapies as a therapeutic alternative.

Methods

Our study is longitudinal, prospective, with 24 months of recruitment, during which 26 migraine patients were included. We worked with a survey sheet, which included the patient’s demographic data, explorations, assessment tests, treatment and evolution. They were included patients of any age, both sexes, with a confirmed migraine and those not included were complicated cases or with pathologies interfering with migraine headaches.

Results

The average age of our population is 42.25 years, Sex-ratio is 0.3 M/F, the average BMI is 26.32 kg/m2 (overweight). Self-medication was present in 12.46%, constituting a major risk of perpetuation of the disease. 88.46% had a socio-professional impact. Analytically, the VAS classes and the mean CRP before and after management were statistically significant (p<0.05). There was a clear correlation between patient improvement and the preventive means used (P=0.05). The insignificance of our results in terms of headache intensity and duration of course could be related to the type of study (longitudinal) (Tessa De Vries & Al, 2020). Self-medication has been widely present due to the lack of the of therapeutic education of our patients (Licia Grazzi & Al, 2023). The same goes for the socio-professional impact of the disease. The results of the CRP monitoring are in clear agreement with the study by (FH Vanmolkot & Al, 2007). Preventive measures are effective (Roberta Messin & al, 2023).

Conclusions

Treat migraine pain early and anticipate and do not wait for the onset of signs of central sensitization. The neuromodulation of pain in itself is synonymous with the risk of the transition to chronicity. Preventive measures are as effective as therapeutics. Immunological monitoring of migraine headaches can be a very reliable means of monitoring.

References

1.Grazzi L, D’Amico D, Guastafierro E, Demichelis G, Erbetta A, Fedeli D, et al. Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study). J Headache Pain. 14 juill 2023;24(1):86.
2.Gudmundsson LS, Aspelund T, Scher AI, Thorgeirsson G, Johannsson M, Launer LJ, et al. C-reactive protein in migraine sufferers similar to that of non-migraineurs: the Reykjavik Study. Cephalalgia Int J Headache. déc 2009;29(12):1301?10.
3.La migraine | Fédération Française de Neurologie [Internet]. [cité 28 janv 2024]. Disponible sur: https://www.ffn-neurologie.fr/grand-public/maladies/la-migraine
4.Une nouvelle ère de traitement pour la migraine?: qu’est-ce qui convient à nos patients?? – Neurologies [Internet]. [cité 28 janv 2024]. Disponible sur: https://neurologies.fr/une-nouvelle-ere-de-traitement-pour-la-migraine-quest-ce-qui-convient-a-nos-patients/
5.Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia Int J Headache. mars 2023;43(3):3331024231152169.
6.Nefti M, Habbouche N, Aouni M, Khelouf M, Messaoudi F. Les céphalées chroniques quotidiennes chez les enfants et les adolescents scolarisés au niveau moyen dans la wilaya de Constantine (Algérie). Rev Neurol (Paris). 30 avr 2015;171.
7.Khelouf M, Benbakhti A, Bouzenada H, Nefti M, Bendini M, Messaoudi F. Les potentiels évoques visuels gardent-ils encore un intérêt diagnostique dans la sclérose en plaques?? Rev Neurol (Paris). 1 avr 2016;172:A87.
8.T de V, Cm V, A M. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther [Internet]. juill 2020 [cité 25 janv 2024];211. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/32173558/
9.Manuels MSD pour le grand public [Internet]. [cité 22 déc 2023]. Migraines – Troubles du cerveau, de la moelle épinière et des nerfs. Disponible sur: https://www.msdmanuals.com/fr/accueil/troubles-du-cerveau,-de-la-moelle-%C3%A9pini%C3%A8re-et-des-nerfs/c%C3%A9phal%C3%A9es/migraines
10.Roussel N, Barbara C, Dolphens M, Struyf F, Danneels L, Nijs J, et al. Sensibilisation centrale et modification du traitement central de la doleur chez les patients souffrant de lombalgies (French version). Ortho – Rheumato. 5 juill 2014;12:29?35.

Presenting Author

Mohamed Ridha Khelouf

Poster Authors

Mohamed ridha KHELOUF

Dr

Regional University Military Hospital of Constantine (RUMHC)

Lead Author

Topics

  • Assessment and Diagnosis